A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2021-02-22
Target enrollment:
Participant gender:
Summary
This is a study designed to evaluate the efficacy and safety of oral YY-20394 in patients
with R/R follicular non-Hodgkin's lymphoma who have failed at least two prior systemic
therapies.